Logo
x

Search category

Subscribe Now

BeiGene

BeiGene Receives EMA’s CHMP Positive Opinion Recommending Approval of Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

BeiGene Receives EMA’s CHMP Positive Opinion Recommending Approval of Tislelizumab for Advanced or Metastatic Esophageal Squamous...

  • July 21, 2023
BeiGene Reports the US FDA Acceptance of sNDA for Brukinsa + Obinutuzumab for Adult Patients with R/R Follicular Lymphoma

BeiGene Reports the US FDA Acceptance of sNDA for Brukinsa + Obinutuzumab for Adult Patients with R/R Follicular Lymphoma

  • July 13, 2023
BeiGene Collaborated with DualityBio to Advance Differentiated Antibody Drug Conjugate Therapy for Solid Tumors

BeiGene Collaborated with DualityBio to Advance Differentiated Antibody Drug Conjugate Therapy for Solid Tumors

  • July 10, 2023
BeiGene’s Brukinsa (zanubrutinib) Receives the US FDA’s Approval for Chronic Lymphocytic Leukemia

BeiGene’s Brukinsa (zanubrutinib) Receives the US FDA’s Approval for Chronic Lymphocytic Leukemia

  • January 20, 2023
BeiGene Reports the NMPA’s Acceptance of sBLA for Tislelizumab for 1L Treatment of Hepatocellular Carcinoma

BeiGene Reports the NMPA’s Acceptance of sBLA for Tislelizumab for 1L Treatment of Hepatocellular Carcinoma

  • January 2, 2023
Insights+: EMA Marketing Authorization of New Drugs in November 2022

Insights+: EMA Marketing Authorization of New Drugs in November 2022

  • December 28, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.